| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 11/14/2023 | 0.85% | Stephens & Co. | → $13 | Reiterates | Equal-Weight → Equal-Weight |
| 10/10/2023 | 0.85% | Stephens & Co. | → $13 | Reiterates | Equal-Weight → Equal-Weight |
| 07/06/2023 | — | Argus Research | Downgrades | Buy → Hold | |
| 04/12/2023 | 0.85% | Stephens & Co. | → $13 | Initiates Coverage On | → Equal-Weight |
| 02/01/2023 | 43.52% | Piper Sandler | $17 → $18.5 | Downgrades | Overweight → Neutral |
| 12/07/2022 | 101.71% | Argus Research | → $26 | Upgrades | Hold → Buy |
| 11/18/2022 | 55.16% | JP Morgan | $19 → $20 | Maintains | Underweight |
| 11/09/2022 | 78.43% | Goldman Sachs | $22 → $23 | Upgrades | Neutral → Buy |
| 09/16/2022 | — | Keybanc | Initiates Coverage On | → Sector Weight | |
| 07/12/2022 | 62.92% | Goldman Sachs | → $21 | Initiates Coverage On | → Neutral |
| 06/10/2022 | 31.89% | Piper Sandler | $19 → $17 | Maintains | Neutral |
| 05/06/2022 | 47.4% | Piper Sandler | $22 → $19 | Maintains | Neutral |
| 03/18/2022 | 70.67% | Piper Sandler | $19 → $22 | Maintains | Neutral |
| 03/04/2022 | 101.71% | Deutsche Bank | $20 → $26 | Upgrades | Hold → Buy |
| 03/03/2022 | 86.19% | SVB Leerink | $22 → $24 | Maintains | Outperform |
| 01/25/2022 | 70.67% | SVB Leerink | $19 → $22 | Upgrades | Market Perform → Outperform |
| 11/23/2021 | 55.16% | Deutsche Bank | $18 → $20 | Maintains | Hold |
| 08/06/2021 | 47.4% | RBC Capital | $17 → $19 | Maintains | Outperform |
| 08/06/2021 | 47.4% | SVB Leerink | $17 → $19 | Maintains | Market Perform |
| 05/26/2021 | 31.89% | SVB Leerink | $16 → $17 | Maintains | Market Perform |
| 04/30/2021 | 24.13% | SVB Leerink | $15 → $16 | Maintains | Market Perform |
| 04/30/2021 | 39.64% | Canaccord Genuity | $17 → $18 | Maintains | Buy |
| 03/02/2021 | — | Argus Research | Downgrades | Buy → Hold | |
| 02/26/2021 | 16.37% | SVB Leerink | $16 → $15 | Maintains | Market Perform |
| 11/25/2020 | 28.01% | B of A Securities | $14 → $16.5 | Maintains | Buy |
| 10/19/2020 | 0.85% | Baird | → $13 | Downgrades | Outperform → Neutral |
| 10/14/2020 | 0.85% | Cantor Fitzgerald | $9 → $13 | Maintains | Neutral |
| 10/14/2020 | 0.85% | SVB Leerink | $10 → $13 | Maintains | Market Perform |
| 08/24/2020 | -30.18% | JP Morgan | $8 → $9 | Maintains | Neutral |
| 08/11/2020 | -37.94% | Morgan Stanley | $6 → $8 | Maintains | Underweight |
| 08/03/2020 | -22.42% | RBC Capital | $8 → $10 | Maintains | Outperform |
| 07/31/2020 | -30.18% | Cantor Fitzgerald | $6 → $9 | Maintains | Neutral |
| 07/31/2020 | -22.42% | SVB Leerink | $6 → $10 | Maintains | Market Perform |
| 07/21/2020 | -57.33% | Goldman Sachs | $6.5 → $5.5 | Downgrades | Neutral → Sell |
| 05/13/2020 | -53.45% | Morgan Stanley | $5 → $6 | Maintains | Underweight |
| 05/13/2020 | -45.69% | SunTrust Robinson Humphrey | $6 → $7 | Maintains | Hold |
| 05/08/2020 | -53.45% | SVB Leerink | $8 → $6 | Maintains | Market Perform |
| 05/08/2020 | -53.45% | Cantor Fitzgerald | $8 → $6 | Reiterates | → Neutral |
| 04/22/2020 | -45.69% | Jefferies | $10.5 → $7 | Downgrades | Buy → Hold |
| 04/21/2020 | -37.94% | RBC Capital | → $8 | Initiates Coverage On | → Outperform |
| 03/05/2020 | -30.18% | SunTrust Robinson Humphrey | $11 → $9 | Maintains | Hold |
| 03/04/2020 | -14.66% | Deutsche Bank | $12 → $11 | Maintains | Hold |
| 03/03/2020 | -53.45% | CFRA | $9 → $6 | Maintains | Strong Sell |
| 03/03/2020 | -22.42% | Baird | $13 → $10 | Maintains | Outperform |
| 03/03/2020 | -37.94% | Cantor Fitzgerald | $11 → $8 | Reiterates | → Neutral |
| 11/26/2019 | -10.78% | UBS | → $11.5 | Initiates Coverage On | → Neutral |
| 09/26/2019 | -14.66% | Deutsche Bank | → $11 | Initiates Coverage On | → Hold |
| 02/25/2019 | -6.9% | Citigroup | $14 → $12 | Downgrades | Buy → Neutral |
| 02/22/2019 | — | Keybanc | Downgrades | Overweight → Sector Weight | |
| 02/22/2019 | -6.9% | Citigroup | $14 → $12 | Downgrades | Buy → Neutral |
| 01/18/2019 | — | Keybanc | Upgrades | Sector Weight → Overweight | |
| 11/14/2018 | — | Argus Research | Downgrades | Buy → Hold |
What is the target price for Veradigm (MDRX)?
The latest price target for Veradigm (NASDAQ: MDRX) was reported by Stephens & Co. on November 14, 2023. The analyst firm set a price target for $13.00 expecting MDRX to rise to within 12 months (a possible 0.85% upside). 7 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Veradigm (MDRX)?
The latest analyst rating for Veradigm (NASDAQ: MDRX) was provided by Stephens & Co., and Veradigm reiterated their equal-weight rating.
When is the next analyst rating going to be posted or updated for Veradigm (MDRX)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Veradigm, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Veradigm was filed on November 14, 2023 so you should expect the next rating to be made available sometime around November 14, 2024.
Is the Analyst Rating Veradigm (MDRX) correct?
While ratings are subjective and will change, the latest Veradigm (MDRX) rating was a reiterated with a price target of $0.00 to $13.00. The current price Veradigm (MDRX) is trading at is $12.89, which is within the analyst's predicted range.